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1. Introduction 
Bovine blood plasma contains at least two 
kininogens, viz., high-molecular weight (HMW) and 
low-molecular weight (LMW) kininogen; each consists 
of a single polypeptide chain with a molecular weight 
of 76 000 or 50 000, respectively [I] . Both of these 
include the bradykinin moiety in their inner portions 
surrounded by a disulfide loop [2]. Upon incubation 
with plasma kallikrein or snake venom kininogenase, 
they yield the corresponding kinin-free proteins 
which consist of a heavy and a light chain [2] derived, 
respectively, from the NHz- and COOH-terminal 
portions of the parent molecule [3] . The heavy 
chains have the COOH-terminal sequence -Leu-Met- 
LysOH [4], giving rise to the speculation that the 
heavy chain is contiguous with the kinin moiety in 
both kininogens, inasmuch as Met-Lys-bradykinin 
has been isolated from bovine plasma [5]. However, 
this sequence does not agree with those of the two 
kinin-containing peptides, Ser-Arg-Met-Lys- 
bradykinin and Gly-Arg-Met-Lys-bradykinin, 
which were isolated by Hochstrasser and Werle [6] 
from the peptic digest of bovine plasma Cohn fraction 
IV-6. To resolve this contradiction, we have re-examined 
bovine kininogen and established the sequence of 
residues preceding the kinin moiety. The strategy used 
was to prepare a chemically modified HMW kininogen, 
digest it with pancreatic kallikrein, isolate the kinin- 
containing peptide from the digest, and determine 
its amino acid sequence. The results indicate that the 
sequence is Ser-Lcu-Met-Lys-bradykinin, showing 
that the COOH-terminus of the heavy chain is indeed 
juxtaposed to the kinin moiety. 
2. Materials and methods 
Highly purified HMW kininogen was prepared from 
fresh bovine plasma by a method described previously 
[ 1 ] . Porcine pancreatic kallikrein was a generous gift 
from Dr T. Takami, Ajinomoto Co., Tokyo. Chloramine 
T and citraconic anhydride were obtained from 
Nakarai Co., Kyoto. Synthetic bradykinin and its 
derivatives were products of the Protein Research 
Foundation, Osaka. Kinin activity was assayed by its 
ability to cause smooth muscle contraction of isolated 
rat uterus, and the results were expressed in terms of 
the mass of purified bradykinin exhibiting equivalent 
activity [7]. Amino acid sequence was determined by 
the dansyl-Edman degradation procedure which was 
described in detail previously [8,9] . Reduced and 
carboxymethylated (RCM) HMW kininogen (360 mg), 
which was prepared according to the method of 
Crestfield et al. [lo] , was citraconylated at pH 8.4 
in 15 ml of 8 M urea with 400 ~1 of citraconic anhy- 
dride [ 1 l] . Selective oxidation of the methionine 
residues of citraconyl-RCM HMW kininogen (2 12 mg) 
was performed at room temperature for 20 min in 
30 ml of 0.2 M Tris-HCl buffer, pH 8.7, with 25 mg 
of chloramine T [ 121. 
3. Experimental 
The chemically modified HMW kininogen (210 mg) 
was incubated at 37°C with 1.3 mg of pancreatic 
kallikrein in 30 ml of 0.2 M NH4HC0a buffer, pH 8.8. 
After incubation for 8 h, 0.1 M diisopropylphosphoro- 
fluoridate was added to give a final concentration of 
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6.6 X 10e3 M, whereupon the mixture was allowed 
to stand for 1 h at 37°C and then lyophilized. The 
kallikrein digest thus obtained was treated with 20 ml 
of 10% acetic acid for 6 h to remove the citraconyl 
groups, and the mixture was lyophilized. For reduc- 
tion of methionine sulfoxide, the dried material was 
further treated with 6 ml of 20% aqueous 2-mercap- 
toethanol at room temperature for 2 days. The 
resulting deblocked and reduced product was then 
gel-filtered through a column of Sephadex G-50 in 
10% acetic acid, and the fractions were assayed for 
kinin activity (fig.1). Those which exhibited activity 
were re-assayed after trypsin digestion. Most of the 
kinin activity was found in a symmetrical peak 
spanning fractions 101- 1 IO (fig. 1). These fractions 
were pooled and further purified on a column of 
Sephadex G-25 (superfine, 2 X 145 cm) in 10% 
acetic acid; a single peak of kinin activity was found 
at an elution volume of 240-262 ml. This portion 
of the eluate was lyophilized, and one fourth of the 
material obtained was applied to a column of CM- 
cellulose (CM-32) equilibrated with 0.05 M pyridine- 
acetate buffer, pH 5.0. Linear gradient elution was 
carried out as described in the legend of fig.2. Two 
peaks with kinin activity, designated Kr and Kz, were 
detected (fig.2). Each exhibited a single spot after 
cellulose plate (E. Merck) thin layer chromatography 
in n-butanol/pyridine/acetic acid/water (15 : 10 : 
3 : 12, by vol.,). The R, values were as follows; Kr , 
60 80 loo 120 140 
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Fig.1. Fractionation of the pancreatic kallikrein digest of 
oxidized-citraconyl-RCM derivative of bovine plasma HMW 
kininogen on a column of Sephadex G-50. A sample (210 mg) 
of this derivative was digested with kallikrein, treated to 
remove the citraconyt groups and to reduce the methionine 
sulfoxide residues, applied to the column (2.3 X 139 cm) 
and subsequently eluted with 10% acetic acid at a flow rate 
of 25 ml/h. 
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Fig.2. Separation of kinin-containing peptides by CM-cellulose 
(CM-32) column chromatography. A pooled peptide fraction 
with kinin activity was chromatographed on a column 
(1 X 37 cm) of CM-cellulose with a linear gradient (total 
volume 1200 ml) from 0.05-0.5 M pyridine-acetate buffer, 
pH 5.0. The kinin activity was assayed after trypsin digestion. 
0.58; Ka, 0.68; bradykinin, 0.63; Lys-bradykinin, 
0.53; Met-Lys-bradykinin. 0.57. The kinin specific 
activity of isolated Kr and Kz was about one third 
that of synthetic bradykinin. However, both showed 
almost the same activity as bradykinin after treatment 
with trypsin, indicating that both materials must 
contain bradykinin or an equivalent moiety. 
Table 1 shows the amino acid compositions of Kr 
and Kz. Each contains one mole of Leu, Ser, Met, and 
Lys, in addition to the residues representing the 
amino acid composition of bradykinin. The NH*- 
terminal sequence of both was found to be Ser-Leu- 
Met-Lys-Arg- . After the fourth step of the Edman 
degradation of Kr and K2 had been completed, the 
peptides were dansylated, and the resulting materials 
were subjected to cellulose plate thin layer chromato- 
graphy (n-butanollacetic acid/water = 4 : 1 : 5, v/v/v), 
along with the dansyl derivatives of bradykinin, Lys- 
bradykinin and Met-Lys-bradykinin. The DNS- 
derivatives of both peptides showed an R, value 
identical with that of DNS-bradykinin. These results 
indicate that the total amino acid sequence of the two 
kinin-containing peptides, Kr and Kz, must be as 
follows: 
Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Phe- 
Ser-Pro-Phe-Arg 
After Kr and K2 were treated with 30% aqueous 
2-mercaptoethanol at 37°C for 24 h, Kr gave the same 
Rf value as Kz on thin layer chromatography in the 
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Table 1 
Amino acid compositions of the isolated kinin-containing peptides, K, and K, 
Amino acid K, K, Bradykinin 
Residues per molecule 
Ser 
pro 
ClY 
Met 
LeU 
F%e 
LYS 
A% 
Total 
1.8(2) 
3.0(3) 
1.1(l) 
1.0(l) 
1.0(l) 
2.0(2) 
1.1(l) 
2.0(2) 
13 
1.8(2) 1 
3.0(3) 3 
1.1(l) 1 
1.0(l) _ 
1.0(l) _ 
2.0(2) 2 
1.1(l) _ 
1.9(2) 2 
13 9 
Approximately 50 nmol of each sample was hydrolyzed in 0.5 ml of 5.7 N HCl 
at 110°C for 24 h and analyzed with a Model JLC-SAH amino acid analyzer [ 131. 
system used above. On the other hand, the R, value 
of KZ, 0.68, did not change with this treatment. It 
seems, therefore, that the chromatographic difference 
between Kr and K2 arose from the fact that the 
methionine residue in Kr was still in the oxidized 
form. 
4. Discussion 
In the past it has proved very difficult to isolate 
active peptide containing portions of the kininogen 
molecule abutting the NHz-terminus of the kinin 
moiety because the -Met-Lys-Arg- sequence is 
very susceptible to proteinases such as trypsin, 
plasmin and kallikrein. Therefore, in the present 
study we attempted chemical modification of the 
amino acid residues in this region prior to enzymic 
treatment of the kininogen. The success of this 
approach is indicated by the isolation of an active 
peptide with the sequence Ser-Leu-Met-Lys- 
bradykinin. The I-eu-Met-Lys- sequence is consistent 
with the COOH-terminal sequence of the HMW heavy 
chain previously determined [4] and, moreover, 
proves the contiguity of the HMW heavy chain and 
kinin moiety in the kininogen. 
In 1966, Habermann and Helbig [ 141 suggested 
that the residue preceding Met-Lys-bradykinin 
might be leucine, although the experimental data have 
not been reported. Our results confirm their suggestion, 
but do not support the sequence Ser (and Gly)-Arg- 
Met-Lys-bradykinin reported by Hochstrasser and 
Werle [6]. However, there remains the possibility that 
the peptic fragment isolated by the latter investigators 
could have been derived from an unknown kininogen 
other than that used in the present study. We have not 
yet identified a kinin-containing peptide, Ser-Leu-- 
Met-Lys-bradykinin, from bovine LMW kininogen. 
It seems, however, that this sequence must occur in 
the corresponding region of the LMW kininogen, 
inasmuch as both HMW- and LMW heavy chains have 
the same COOH-terminal sequence, viz., Leu-Met- 
LysOH [4]. 
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